Paris, November 26, 2025 - Damae Medical, a French pioneer in imaging and AI for skin cancers, announces a €15M Series B funding round led by Creadev, with participation from Kurma Partners, ISPB, and BNP Paribas Développement.

This funding will accelerate the deployment of the deepLive™ device, helping dermatologists provide faster, more accurate, and non-invasive care.

Today, when doubts remain after the clinical examination, the standard pathway relies on biopsy, which requires several appointments and delays therapeutic decision-making. deepLive™ is gradually being integrated into clinical guidelines as a new reference tool, offering immediate cellular visualization and enabling faster medical decisions.

Developed from the work of Prof. Arnaud Dubois at the Charles Fabry Laboratory (CNRS, Institut d’Optique, Université Paris-Saclay) and a decade of research, the LC-OCT technology integrated into deepLive™ provides real-time, non-invasive cellular-scale imaging of the skin. This 3D digital biopsy offers patients an initial diagnostic orientation during the consultation, without waiting for laboratory results.

The technology also makes it possible to assess the extent of lesions when they need to be removed and to optimize surgical margins, reducing the risk of incomplete excision while preserving as much healthy skin as possible. More than 250 scientific publications validate the effectiveness of this technology, which remains unmatched today.

“Damae offers an essential solution to improve the management of skin cancers and accelerate dermatology research with new data,” says Marc Chipot, Investment Director at Creadev. “We are impressed by the company’s maturity in both optics and AI and proud to support such a talented team capable of establishing new standards in close collaboration with physicians.”

“deepLive™ is now fully integrated into the daily practice of its first users, in France and internationally, allowing the company to enter this new scale-up phase with confidence. We are pleased to continue supporting Damae with our Growth fund,” say Jean-François Rivassou and Philippe Peltier, Managing Partners at Kurma Partners.